Conclusions
The results of targeted levels of platelet inhibition cannot be extrapolated between different clinical trials of GP IIb-IIIa antagonists unless the same assay is used. Dalteparin, compared with UFH, does not enhance platelet inhibition or receptor occupancy by abciximab, as demonstrated by means of 3 separate assays. (Am Heart J 2003;145: e6.)
Platelet glycoprotein (GP) IIb-IIIa antagonists have been demonstrated in controlled clinical trials to reduce adverse cardiac events in patients with acute coronary syndromes 1 and in patients undergoing percutaneous coronary intervention (PCI).
2, 3 The results of the GOLD (AU-Assessing Ultegra) multicenter study 4 demonstrate that, in patients undergoing PCI, the degree of platelet inhibition as determined by means of the use of the Ultegra Rapid Platelet Function Analyzer ([RPFA] Accumetrics, San Diego, Calif) correlates with the development of major adverse cardiac events. In animal and clinical studies, Ն80% GP IIb-IIIa occupancy with abciximab is associated with reduced clinical events. 5 However, the interchangeability of different assays of GP IIb-IIIa antagonist-induced inhibition of platelet function remains uncertain.
Platelet activation results in an increase in the number of surface GP IIb-IIIa molecules. 6 Low molecular weight heparins (LMWHs) are associated with less platelet activation than unfractionated heparin (UFH). 7, 8 Therefore, the use of LMWH may allow for reduced dosages of GP IIb-IIIa antagonist, while maintaining high levels of platelet inhibition similar to "full dose" GP IIb-IIIa antagonist therapy in conjunction with UFH.
There has been interest in measuring the degree of platelet inhibition by GP IIb-IIIa antagonist therapy. Although 80% inhibition is commonly held to be an appropriate therapeutic level, the exact level may depend on the type of assay used. In the recently published GOLD study, 4 a significant correlation was shown between platelet inhibition by a GP IIb-IIIa antagonist, as determined by means of the Ultegra RPFA and major adverse cardiac events (MACE). In this study, we therefore compared the Ultegra RPFA with 2 other typical methods for measuring platelet inhibition with GP IIb-IIIa antagonists: a GP IIb-IIIa receptor occupancy assay and binding of the activated GP IIb-IIIaspecific monoclonal antibody PAC1.
We addressed 2 issues in this study. First, in patients with unstable angina undergoing PCI with planned abciximab administration, we assessed the degree of platelet inhibition as measured by means of 3 independent assays. Second, we assessed whether the LMWH dalteparin, compared with UFH, enhances platelet inhibition with abciximab.
Methods

Percutaneous coronary intervention
After obtaining approval by the Institutional Review Committee of The Christ Hospital (Cincinnati, Ohio) and written informed consent of patients, we randomly assigned 40 patients with unstable angina pectoris (Braunwald class II-III 9 ) and coronary anatomy suitable for PCI in a blinded fashion to receive either 60 IU/kg of dalteparin or 70 U/kg of UFH intravenously at the time of PCI. Five minutes after UFH or dalteparin administration, abciximab was administered intravenously in half of the standard bolus dose (0.125 mg/kg), followed in 10 minutes by the remainder (0.125 mg/kg). Initiation of the standard 12-hour intravenous infusion of abciximab (0.125 g/kg/min, maximum 10 g/h) began immediately after administration of the second abciximab bolus. Patients were excluded from enrollment when they had received any heparin during the 48 hours before PCI, had a known allergy to aspirin or thienopyridines, or had earlier abciximab-associated thrombocytopenia. Similarly, patients who had undergone recent (Ͻ6 weeks) surgery or trauma or had an earlier (within 6 months) stroke or gastrointestinal/ genitourinary bleeding were excluded from participation. All patients received 325 mg of aspirin orally before and daily after PCI. Clopidogrel (300 mg load, 75 mg daily) was administered orally immediately after PCI in all patients who underwent coronary stent deployment. PCI was performed with standard techniques by experienced Ohio Heart Health Center operators (Ͼ300 PCIs/operator/y) at a single center (Christ Hospital). Vascular access sheaths were removed 4 hours after the study drug bolus was given. Hemostasis was maintained by means of local manual compression (30 minutes), followed by pneumocompression (Femostop, Radi Medical Systems, Reading, Mass) for 4 hours. Vascular closure devices were not used. Monitoring of anticoagulation (activated clotting time, activated partial thromboplastin time) was not performed, and no heparin was administered after PCI. The dose of UFH administered in this study (70 U/kg) was previously demonstrated to be safe and effective in randomized trials of abciximab therapy for PCI. 10 , 11 The dose of dalteparin (60 IU/kg) was selected from an earlier pilot trial experience, which demonstrated consistent antithrombotic efficacy (antifactor Xa activity exceeding 0.6 U/mL) and absence of clinical thrombotic events when administered in combination with abciximab in patients undergoing PCI. 12 
Assay time points and clinical outcomes
Platelet inhibition assays were performed as described on citrated (3.2%) venous blood obtained at baseline (before administration of either UFH or dalteparin), 5 minutes after administration of either UFH or dalteparin, 10 minutes after administration of each half-dose bolus of abciximab, 8 to 10 hours after administration of either UFH or dalteparin, and 16 to 24 hours after administration of either UFH or dalteparin. Clinical parameters assessed in the hospital included death, myocardial infarction (creatinine kinase-MB, or creatinine kinase in the absence of measured MB fraction, Ͼ3 times the upper limit of normal), and urgent revascularization (PCI or surgery). Bleeding events and requirements for blood transfusion were also assessed. Bleeding events were determined to be major or minor on the basis of the Thrombolysis In Myocardial Infarction (TIMI) Study Group designation, as previously described. 13 
Ultegra rapid platelet function assay
The Ultegra RPFA was used as previously described. 14 The RPFA is a means of measuring the increase in light transmittance of anticoagulated whole blood with time as a result of the agglutination of platelets (via unblocked surface GP IIbIIIa) with fibrinogen-coated micro-beads, after platelet activation induced by means of iso-TRAP (thrombin receptor activating peptide).
Receptor occupancy assay
This whole blood quantitative no-wash assay of total and free GP IIb-IIIa receptors measured by flow cytometry has been previously described. 15 Citrated whole blood was mixed 1:1 (vol/vol) with a cocktail of kinase inhibitors (Beckman Coulter, Miami, Fla) (1/200 dilution final), and phosphatase inhibitors (Beckman Coulter) (1/50 dilution final), diluted in Hanks' Balanced Salt Solution (GIBCO BRL, Grand Island, NY), then placed at 4°C and shipped overnight to the Center for Platelet Function Studies at the University of Massachusetts Medical School in Worcester, Mass.
Our method was identical to that of Hezard et al, 15 except the samples were fixed in 0.5% formalin at the end of the labeling procedure. In brief, total GP IIb-IIIa receptors were measured by the binding of monoclonal antibody Mab2 (BioCytex, Marseilles, France), the binding of which to GP IIIa (CD61) is not inhibited by abciximab. Free GP IIb-IIIa receptors were measured by the binding of Mab1 (BioCytex) to GP IIIa, an interaction inhibited by abciximab. Analysis was performed in a FACSCalibur flow cytometer (Becton Dickinson, San Jose, Calif) equipped with a 488-nm argon ion laser, standard 3-color filter configuration, and CELLQuest cell analysis software (Becton Dickinson). Calibration beads were used to determine the number of antibodies bound and to generate a standard curve to calculate the absolute numbers of occupied versus unoccupied GP IIb-IIIa receptors.
PAC1 binding assay
Monoclonal antibody PAC1 only binds to the activated conformation of GP IIb-IIIa and thus mimics the activation-dependent binding of fibrinogen to platelets. 16 Anticoagulated whole blood was first diluted 1:10 in modified HEPES Tyrode's buffer (137 mmol/L NaCl, 2. The percent platelet inhibition was calculated by use of the equation 100% minus the ratio of PAC1 geometric mean fluorescence intensity at any given time point relative to the baseline. PAC1 mean fluorescence intensity was stable for at least 96 hours in samples stored and shipped at 4°C (data not shown).
Statistical analysis
In comparing the distribution of baseline characteristics in randomized patients, differences in continuous variables were compared with t tests, whereas differences in categorical variables were compared by use of the 2 tests. All analyses were performed with SAS statistical software (SAS Inc, Cary, NC).
Results
Clinical characteristics and outcomes
Baseline characteristics of the 2 treatment groups are shown in Table I . There were no statistically significant differences between patients receiving UFH and patients receiving dalteparin in age, sex, history of myocardial infarction, unstable angina, hypertension, hypercholesterolemia, use of cigarettes, heart failure, peripheral vascular disease, obstructive lung disease, prior PCI or bypass grafting surgery, or medication use. Patients receiving dalteparin were more likely to have diabetes mellitus than patients receiving UFH.
Sixteen patients in each group underwent stent placement. Four patients in each group had only balloon PCI. One patient in the UFH-treated group and 1 patient in the dalteparin-treated group had an elevation of creatine kinase-MB after the intervention. There were no bleeding complications in the patients randomized to receive UFH. Two patients receiving dalteparin had a minor bleeding event (hematuria and vascular access site oozing), and a hematoma developed in 1 patient in the dalteparin-treatment group. Thrombocytopenia developed in one patient receiving dalteparin.
Platelet inhibition
As shown in Table II , at each time point the mean percent platelet inhibition as determined by both the PAC1 assay and receptor occupancy assay was less than the inhibition determined by the RPFA.
Ten minutes after the first half-dose bolus of abciximab was given, the mean percent platelet inhibition was 73% Ϯ 3%, as determined by means of the RPFA (mean Ϯ SEM), 57% Ϯ 3% by means of the PAC1 assay, and 63% Ϯ 3% by means of the receptor occupancy assay (Table II) . At this time point, as determined by the Ultegra RPFA, 48% of patients achieved Ͼ80% platelet inhibition and 9% of patients achieved Ͼ95% platelet inhibition (Table II) . As determined by the PAC1 assay, only 8% of patients achieved Ͼ80% platelet inhibition, and no patient achieved Ͼ95% platelet inhibition. As determined by the receptor occupancy assay, 21% of patients achieved Ͼ80% platelet inhibition, and no patient achieved Ͼ95% platelet inhibition (Table II) . Ten minutes after the second half-dose bolus of abciximab was given, the mean percent platelet inhibition was 97% Ϯ 1% as determined by means of the RPFA, 80% Ϯ 1% by means of the PAC1 assay, and 88% Ϯ 1% by means of the receptor occupancy assay (Table II) . At this time point, as determined by the RPFA, all patients achieved Ͼ80% platelet inhibition, and 79% of patients achieved Ͼ95% platelet inhibition (Table II) . These data are similar to those reported in the GOLD study, 4 in which 10 minutes after the full bolus dose of abciximab was given the mean percent platelet inhibition was 96%, and 71% of patients achieved Ͼ95% platelet inhibition, as determined by the RPFA. In contrast to the RPFA, as determined by the PAC1 assay, 10 minutes after the second half-dose bolus of abciximab was given only 61% of patients achieved Ͼ80% platelet inhibition, and no patient achieved Ͼ95% platelet inhibition (Table II, Figure 1) . Similarly, only 3% of patients achieved Ͼ95% platelet inhibition as determined by the receptor occupancy assay, whereas 79% of patients achieved Ͼ95% platelet inhibition as determined by the RPFA (Figure 1) .
At the 8-to 10-hour time point, the mean percent platelet inhibition was 92% Ϯ 2% as determined by the RPFA, 77% Ϯ 3% as determined by the PAC1 assay, and 81% Ϯ 1% as determined by the receptor occupancy assay (Table II) , reflecting a slight decrease in the antiplatelet effects of abciximab despite the continuous intravenous infusion of this drug. Although 94% of patients achieved Ͼ80% platelet inhibition as determined by the RPFA, only 51% of patients achieved Ͼ80% platelet inhibition as determined by the PAC1 assay, and 68% of patients achieved Ͼ80% platelet inhibition as determined by the receptor occupancy assay (Table II) . Consistent with these data, at the 8-hour time point in the GOLD study, 4 94% of the subjects had Ͼ70% platelet inhibition as determined by the RPFA.
Figure 1
Percent platelet inhibition 10 minutes after the administration of the second bolus of abciximab, as determined by means of Ultegra RPFA, receptor occupancy assay, and the PAC1 binding assay in 40 patients with unstable angina undergoing PCI. The shaded area indicates patients with Ͼ95% platelet inhibition. At the 24-hour time point, the mean percent platelet inhibition declined to 68% Ϯ 1%, 75% Ϯ 3%, and 78% Ϯ 1%, as determined by the receptor occupancy assay, the PAC1 assay, and the RPFA, respectively (Table II) . Although 39% of patients still had Ͼ80% platelet inhibition as determined by the RPFA, 55% of patients had Ͼ80% platelet inhibition as determined by the PAC1 assay, and only 5% of patients had Ͼ80% platelet inhibition as determined by the receptor occupancy assay (Table II) .
There were no significant differences between patients receiving dalteparin and patients receiving UFH (Tables III and IV) .
Discussion
Inconsistent clinical benefits in trials of GP IIb-IIIa antagonists may reflect variable (and at times suboptimal) platelet inhibition. 1, 17, 18 In the recently published GOLD study, 4 26% of patients had Ͻ95% platelet inhibition as determined by the Ultegra RPFA 10 minutes after intravenous bolus administration of a GP IIb-IIIa antagonist, and these patients experienced a significantly higher incidence (14.4% vs 6.4%, P ϭ .006) of major adverse cardiac events ([MACEs] composite of death, myocardial infarction, and urgent target vessel revascularization). Furthermore, in the GOLD study, 4 patients whose platelet function was Ͻ70% inhibited, as determined by the RPFA, 8 hours after the start of therapy had a MACE rate of 25%, versus 8.1% for patients whose platelet function was Ͼ70% inhibited (P ϭ .009). These data suggest the need for individualization of doses of GP IIb-IIIa antagonists.
As determined by the RPFA, this study showed a similar variation in platelet inhibition with abciximab to that reported in the GOLD study. 4 However, this study demonstrates that quantification of the degree of abciximab-induced platelet inhibition varies depending on the assay system used. For example, after the second half-dose bolus of abciximab was given, the percent of patients with Ͼ95% platelet inhibition was 79% with the RPFA, 3% with a receptor occupancy assay, and 0% with the PAC1 assay (Table II, Figure 1 ). It is therefore necessary for all platelet function assays to be rigorously tested in clinical trials of GP IIb-IIIa antagonists to determine the optimum degree of platelet inhibition for each device. Furthermore, this study demonstrates that the results of studies performed with different assays are not interchangeable. Because LMWH activates platelets less than UFH does, 7, 8 we hypothesized that the use of a LMWH such as dalteparin may allow reduced doses of GP IIb-IIIa inhibitors in these patients, because less GP IIb-IIIa molecules may be expressed on the platelet surface in an activation-dependent manner. 6 However, in this study of patients with unstable angina receiving abciximab, we demonstrated similar degrees of platelet inhibition with either UFH (70 U/kg) or dalteparin (60 IU/ kg), as determined by the 3 independent assays. Thus, the modest platelet-activating effect of UFH does not appear to impact the dose of GP IIb-IIIa antagonist required to achieve therapeutic platelet inhibition.
